 VANCOUVER, Washington, Dec. 23, 2022 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY CytoDyn or the Company, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time 11:00 a.m. Eastern Time to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time. 